- Home
- CNTB vs CTSO Comparison
CNTB vs CTSO Comparison
Compare CNTB & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTB
- CTSO
- Stock Information
- Founded
- CNTB 2012
- CTSO 1997
- Country
- CNTB United States
- CTSO United States
- Employees
- CNTB N/A
- CTSO N/A
- Industry
- CNTB Biotechnology: Pharmaceutical Preparations
- CTSO Medical/Dental Instruments
- Sector
- CNTB Health Care
- CTSO Health Care
- Exchange
- CNTB Nasdaq
- CTSO Nasdaq
- Market Cap
- CNTB 53.9M
- CTSO 51.6M
- IPO Year
- CNTB 2021
- CTSO N/A
- Fundamental
- Price
- CNTB $1.05
- CTSO $1.03
- Analyst Decision
- CNTB Strong Buy
- CTSO Strong Buy
- Analyst Count
- CNTB 1
- CTSO 3
- Target Price
- CNTB $8.00
- CTSO $4.67
- AVG Volume (30 Days)
- CNTB 28.0K
- CTSO 538.8K
- Earning Date
- CNTB 09-05-2024
- CTSO 03-06-2025
- Dividend Yield
- CNTB N/A
- CTSO N/A
- EPS Growth
- CNTB N/A
- CTSO N/A
- EPS
- CNTB N/A
- CTSO N/A
- Revenue
- CNTB $24,116,000.00
- CTSO $37,739,531.00
- Revenue This Year
- CNTB N/A
- CTSO $9.20
- Revenue Next Year
- CNTB $63.90
- CTSO $11.64
- P/E Ratio
- CNTB N/A
- CTSO N/A
- Revenue Growth
- CNTB N/A
- CTSO 1.80
- 52 Week Low
- CNTB $0.90
- CTSO $0.70
- 52 Week High
- CNTB $2.66
- CTSO $1.59
- Technical
- Relative Strength Index (RSI)
- CNTB 45.74
- CTSO 55.82
- Support Level
- CNTB $1.01
- CTSO $1.00
- Resistance Level
- CNTB $1.40
- CTSO $1.14
- Average True Range (ATR)
- CNTB 0.13
- CTSO 0.09
- MACD
- CNTB -0.01
- CTSO 0.01
- Stochastic Oscillator
- CNTB 25.53
- CTSO 64.40
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.